In vitro inhibition of mitochondrial respiratory rate by antidepressants

Toxicology Letters

Volumn 213, Issue 3, 2012, Pages 345-352

  Hroudová, Jana ^a   Fišar, Zdeněk ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressant; Mitochondria; Mood stabilizer; Respiratory rate

Indexed keywords

AMITRIPTYLINE; CHLORPROMAZINE; FLUOXETINE; KETAMINE; LITHIUM; OLANZAPINE; PROPRANOLOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); TIANEPTINE; VALPROIC ACID;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL RESPIRATION; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENERGY METABOLISM; MITOCHONDRIA; SWINE; TRANQUILIZING AGENTS;

SUIDAE;

EID: 84865281542     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.07.017     Document Type: Article

References (62)

1. Abdel-Razaq W., Kendall D.A., Bates T.E. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochemical Research 2011, 36:327-338.
2. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Letters 2006, 580:5533-5540.
3. Arnould T., Vankoningsloo S., Renard P., Houbion A., Ninane N., Demazy C., Remacle J., Raes M. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. EMBO Journal 2002, 21:53-63.
4. Bachmann R.F., Wang Y., Yuan P., Zhou R., Li X., Alesci S., Du J., Manji H.K. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. International Journal of Neuropsychopharmacology 2009, 12:805-822.
5. Bautista-Ferrufino M.R., Cordero M.D., Sánchez-Alcázar J.A., Illanes M., Fernández-Rodríguez A., Navas P., de Miguel M. Amitriptyline induces coenzyme Q deficiency and oxidative damage in mouse lung and liver. Toxicology Letters 2011, 204:32-37.
6. Boelsterli U.A., Lim P.L. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity?. Toxicology and Applied Pharmacology 2007, 220:92-107.
7. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 1990, 100:509-514.
8. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J., Mattson M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxidants and Redox Signalling 2010, 13:1763-1811.
9. Chan K., Truong D., Shangari N., O'Brien P.J. Drug-induced mitochondrial toxicity. Expert Opinion on Drug Metabolism & Toxicology 2005, 1:655-669.
10. Chance B., Williams G.R. Respiratory enzymes in oxidative phosphorylation. III. The steady state. Journal of Biological Chemistry 1955, 217:409-427.
11. Curti C., Mingatto F.E., Polizello A.C., Galastri L.O., Uyemura S.A., Santos A.C. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Molecular and Cellular Biochemistry 1999, 199:103-109.
12. de Oliveira L., Spiazzi C.M., Bortolin T., Canever L., Petronilho F., Mina F.G., Dal-Pizzol F., Quevedo J., Zugno A.I. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:1003-1008.
13. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disorders 2002, 4:183-194.
14. Durazo S.A., Kadam R.S., Drechsel D., Patel M., Kompella U.B. Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharmaceutical Research 2011, 28:2833-2847.
15. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today 2007, 12:777-785.
16. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicological Sciences 2008, 103:335-345.
17. FiŠar Z., Krulík R., Fuksová K., Sikora J. Imipramine distribution among red blood cells, plasma and brain tissue. General Physiology and Biophysics 1996, 15:51-64.
18. FiŠar Z., Fuksová K., Velenovská M. Binding of imipramine to phospholipid bilayers using radioligand binding assay. General Physiology and Biophysics 2004, 23:77-99.
19. FiŠar Z. Interactions between tricyclic antidepressants and phospholipid bilayer membranes. General Physiology and Biophysics 2005, 24:161-180.
20. FiŠar Z., Hroudová J. Common aspects of neuroplasticity, stress, mood disorders and mitochondrial functions. Activitas Nervosa Superior Rediviva 2010, 52:3-20.
21. FiŠar Z., Hroudová J., Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinology Letters 2010, 31:645-656.
22. FiŠar Z., Hroudová J., Korábečný J., Musílek K., Kuča K. In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity. Toxicology Letters 2011, 201:176-180.
23. Frantz M.C., Wipf P. Mitochondria as a target in treatment. Environmental and Molecular Mutagenesis 2010, 51:462-475.
24. Furuno T., Kanno T., Arita K., Asami M., Utsumi T., Doi Y., Inoue M., Utsumi K. Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochemical Pharmacology 2001, 62:1037-1046.
25. Gnaiger E. Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. International Journal of Biochemistry and Cell Biology 2009, 41:1837-1845.
26. González-Pardo H., Conejo N.M., Arias J.L., Monleón S., Vinader-Caerols C., Parra A. Changes in brain oxidative metabolism induced by inhibitory avoidance learning and acute administration of amitriptyline. Pharmacology Biochemistry and Behavior 2008, 89:456-462.
27. Haas R., Stumpf D.A., Parks J.K., Eguren L. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981, 31:1473-1476.
28. Horobin R.W., Trapp S., Weissig V. Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. Journal of Controlled Release 2007, 121:125-136.
29. Hroudova J., Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinology Letters 2010, 31:336-342.
30. Hroudová J., FiŠar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry and Clinical Neurosciences 2011, 65:130-141.
31. Kaasik A., Kuum M., Joubert F., Wilding J., Ventura-Clapier R., Veksler V. Mitochondria as a source of mechanical signals in cardiomyocytes. Cardiovascular Research 2010, 87:83-91.
32. Karson C.N., Newton J.E., Livingston R., Jolly J.B., Cooper T.B., Sprigg J., Komoroski R.A. Human brain fluoxetine concentrations. Journal of Neuropsychiatry and Clinical Neurosciences 1993, 5:322-329.
33. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders 2000, 2:180-190.
34. Katyare S.S., Rajan R.R. Altered energy coupling in rat heart mitochondria following in vivo treatment with propranolol. Biochemical Pharmacology 1991, 42:617-623.
35. Kuznetsov A.V., Schneeberger S., Seiler R., Brandacher G., Mark W., Steurer W., Saks V., Usson Y., Margreiter R., Gnaiger E. Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion. American Journal of Physiology. Heart and Circulatory Physiology 2004, 286:H1633-H1641.
36. Lauterbach E.C., Victoroff J., Coburn K.L., Shillcutt S.D., Doonan S.M., Mendez M.F. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. Journal of Neuropsychiatry and Clinical Neurosciences 2010, 22:8-18.
37. Lores-Arnaiz S., D'Amico G., Czerniczyniec A., Bustamante J., Boveris A. Brain mitochondrial nitric oxide synthase: in vitro and in vivo inhibition by chlorpromazine. Archives of Biochemistry and Biophysics 2004, 430:170-177.
38. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
39. Maurer I., Möller H.-J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Molecular and Cellular Biochemistry 1997, 174:255-259.
40. Maurer I.C., Schippel P., Volz H.-P. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disorders 2009, 11:515-522.
41. McEwen B.S., Chattarji S., Diamond D.M., Jay T.M., Reagan L.P., Svenningsson P., Fuchs E. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Molecular Psychiatry 2010, 15:237-249.
42. Merlo-Pich M., Deleonardi G., Biondi A., Lenaz G. Methods to detect mitochondrial function. Experimental Gerontology 2004, 39:277-281.
43. Modica-Napolitano J.S., Lagace C.J., Brennan W.A., Aprille J.R. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Archives of Pharmacal Research 2003, 26:951-959.
44. Nahon E., Israelson A., Abu-Hamad S., Varda S.B. Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Letters 2005, 579:5105-5110.
45. Pesta D., Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods in Molecular Biology 2012, 810:25-58.
46. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
47. Ponchaut S., van Hoof F., Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochemical Pharmacology 1992, 43:2435-2442.
48. Quiroz J.A., Gray N.A., Kato T., Manji H.K. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33:2551-2565.
49. Reasor M.J., Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Experimental Biology and Medicine (Maywood, NJ) 2001, 226:825-830.
50. Rezin G.T., Gonçalves C.L., Daufenbach J.F., Fraga D.B., Santos P.M., Ferreira G.K., Hermani F.V., Comim C.M., Quevedo J., Streck E.L. Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. Brain Research Bulletin 2009, 79:418-421.
51. Robinson M.M., Hamilton K.L., Miller B.F. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. Journal of Applied Physiology 2009, 107:8-16.
52. Ross M.F., Da Ros T., Blaikie F.H., Prime T.A., Porteous C.M., Severina I.I., Skulachev V.P., Kjaergaard H.G., Smith R.A., Murphy M.P. Accumulation of lipophilic dications by mitochondria and cells. Biochemical Journal 2006, 400:199-208.
53. Scatena R. Mitochondria and drugs. Advances in Experimental Medicine and Biology 2012, 942:329-346.
54. Schapira A.H.V. Mitochondrial diseases. Lancet 2012, 379:1825-1834.
55. Silva M.F., Ruiter J.P., Illst L., Jakobs C., Duran M., de Almeida I.T., Wanders R.J. Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. Journal of Inherited Metabolic Disease 1997, 20:397-400.
56. Sjövall F., Morota S., Hansson M.J., Friberg H., Gnaiger E., Elmér E. Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Critical Care 2010, 14:R214.
57. Souza M.E., Polizello A.C., Uyemura S.A., Castro-Silva O., Curti C. Effect of fluoxetine on rat liver mitochondria. Biochemical Pharmacology 1994, 48:535-541.
58. Stavrovskaya I.G., Narayanan M.V., Zhang W., Krasnikov B.F., Heemskerk J., Young S.S., Blass J.P., Brown A.M., Beal M.F., Friedlander R.M., Kristal B.S. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. Journal of Experimental Medicine 2004, 200:211-222.
59. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Molecular Psychiatry 2005, 10:900-919.
60. Szewczyk A., Wojtczak L. Mitochondria as a pharmacological target. Pharmacological Reviews 2002, 54:101-127.
61. 2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis. Journal of Pharmacology and Experimental Therapeutics 2012, 342:106-118.
62. Xia Z., Ying G., Hansson A.L., Karlsson H., Xie Y., Bergstrand A., DePierre J.W., Nässberger L. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Progress in Neurobiology 2000, 60:501-512.